Objective: The role of dietary factors in the etiopathogenesis of chronic spontaneous urticaria (CSU) has been a matter of discussion and it is widely accepted that most urticaria cases triggered by food are caused by pseudoallergic reactions. In this prospective study, our aim was to investigate the effect of a pseudoallergen-free diet (PAFD) on disease activity, the need for antihistamine use, and the quality of life in patients with CSU. Materials and Methods: The study included adult patients who were on follow up for CSU for a duration of at least 6 months and had symptoms every day or every other day. The patients were given a food diary, which also included assessment of daily disease activity. The daily Urticaria Activity Score (UAS), the Chronic Urticaria Quality of Life Questionnaire score at baseline and at the 4th week, and frequency of antihistamine use were obtained. According to the change in UAS (∆UAS), the patients’ response to PAFD was classified as strong (∆UAS≥8), partial (8>∆UAS≥4), or no response (∆UAS<4). Results: Twenty-three patients, 19 females (82.6%) and 4 males (17.4%), completed the study, the mean age was 43±4.6 years. According to ∆UAS, 6 patients (26.1%) had strong response, 6 (26.1%) had partial response, and 11 (47.8%) were unresponsive to PAFD. The mean ∆UAS value of the patients who responded to PAFD was 8.1 (min:4, max:15). At the end of the study, 9 (39.1%) patients had a significant improvement in their quality of life. There were 6 (26%) patients who both responded to PAFD and had improved quality of life scores. The frequency of antihistamine use decreased in 10 (43.5%) patients. Conclusion: PAFD may help decrease disease activity in CSU. We observed that the frequency of antihistamine use could be reduced and the patient’s quality of life could be improved by adding PFAD to antihistamine therapy.
{"title":"Effect of a Pseudoallergen-Free Diet in Chronic Spontaneous Urticaria: A Pilot Study","authors":"Esra Saraç, Pelin Kuteyla Can, E. Kocaturk","doi":"10.21911/aai.693","DOIUrl":"https://doi.org/10.21911/aai.693","url":null,"abstract":"Objective: The role of dietary factors in the etiopathogenesis of chronic spontaneous urticaria (CSU) has been a matter of discussion and it is widely accepted that most urticaria cases triggered by food are caused by pseudoallergic reactions. In this prospective study, our aim was to investigate the effect of a pseudoallergen-free diet (PAFD) on disease activity, the need for antihistamine use, and the quality of life in patients with CSU. Materials and Methods: The study included adult patients who were on follow up for CSU for a duration of at least 6 months and had symptoms every day or every other day. The patients were given a food diary, which also included assessment of daily disease activity. The daily Urticaria Activity Score (UAS), the Chronic Urticaria Quality of Life Questionnaire score at baseline and at the 4th week, and frequency of antihistamine use were obtained. According to the change in UAS (∆UAS), the patients’ response to PAFD was classified as strong (∆UAS≥8), partial (8>∆UAS≥4), or no response (∆UAS<4). Results: Twenty-three patients, 19 females (82.6%) and 4 males (17.4%), completed the study, the mean age was 43±4.6 years. According to ∆UAS, 6 patients (26.1%) had strong response, 6 (26.1%) had partial response, and 11 (47.8%) were unresponsive to PAFD. The mean ∆UAS value of the patients who responded to PAFD was 8.1 (min:4, max:15). At the end of the study, 9 (39.1%) patients had a significant improvement in their quality of life. There were 6 (26%) patients who both responded to PAFD and had improved quality of life scores. The frequency of antihistamine use decreased in 10 (43.5%) patients. Conclusion: PAFD may help decrease disease activity in CSU. We observed that the frequency of antihistamine use could be reduced and the patient’s quality of life could be improved by adding PFAD to antihistamine therapy.","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45253284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Management of Acute and Chronic Urticaria","authors":"I. Yilmaz, G. PAÇACI ÇETİN, B. Arslan, M. Türk","doi":"10.21911/aai.093","DOIUrl":"https://doi.org/10.21911/aai.093","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48123572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zeliha YANGINLAR BROHI, H. Guvenir, I. Kulhas Celik, M. Toyran, E. Civelek, T. Giniş, B. Buyuktiryaki, C. Kocabaş, E. Dibek Mısırlıoğlu
{"title":"Clinical Characteristics and Prognosis of Legume Allergy in Children","authors":"Zeliha YANGINLAR BROHI, H. Guvenir, I. Kulhas Celik, M. Toyran, E. Civelek, T. Giniş, B. Buyuktiryaki, C. Kocabaş, E. Dibek Mısırlıoğlu","doi":"10.21911/aai.024","DOIUrl":"https://doi.org/10.21911/aai.024","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48048914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Esenboğa, Hande Ucler, Sevil OSKAY HALACLI, Çağman Tan, Nergis Kendirci, Yu Zhang, H. Su, D. Çağdaş, I. Tezcan
{"title":"Mutation in BTK Gene Causing an Atypical Presentation of XLA","authors":"S. Esenboğa, Hande Ucler, Sevil OSKAY HALACLI, Çağman Tan, Nergis Kendirci, Yu Zhang, H. Su, D. Çağdaş, I. Tezcan","doi":"10.21911/aai.033","DOIUrl":"https://doi.org/10.21911/aai.033","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49036625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E. Özdemir, Esra Karabiber, E. Damadoğlu, G. Karakaya, A. Kalyoncu
{"title":"Visual Analogue Scale is A Simple and Quick Tool to Evaluate Drug Reaction Severity","authors":"E. Özdemir, Esra Karabiber, E. Damadoğlu, G. Karakaya, A. Kalyoncu","doi":"10.21911/aai.019","DOIUrl":"https://doi.org/10.21911/aai.019","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49281482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Can, Deniz Eyice Karabacak, C. Tüzer, Alpay Medet ALİBEYOĞLU2, Murat Köse, S. Demir, S. Büyüköztürk, B. Çolakoğlu, A. Gelincik
Objective: The clinical features of COVID-19 range from asymptomatic disease to severe pneumonia or even death. Therefore, many researchers have investigated the factors that could affect the severity of COVID-19. We aimed to assess the impact of aero-allergen sensitization and allergic diseases on the severity of COVID-19. Materials and Methods: We included 60 adult patients with symptomatic COVID-19 and allocated them into two groups equal in number as having severe and non-severe COVID-19. We evaluated the demographic features and allergic diseases in addition to clinical, laboratory and radiological findings of COVID-19. Skin prick tests (SPTs) with common aero-allergens, serum total IgE levels and blood eosinophil counts were evaluated 3 months after the patient’s recovery from COVID-19.Results: The mean age of the patients was 52 ± 11 years and 73.3% of the patients were male. There was no significant difference between the two groups in terms of age, gender, smoking habits, obesity and comorbidities. Although the frequency of sensitization to aero-allergens and the allergic diseases were similar, the history of allergic diseases in the family was higher in the severe group (p<0.001). The polysensitization in SPTs was associated with the presence of a cytokine storm during the infection (p=0.02). Total IgE levels and blood eosinophil counts were not significantly different between the two groups.Conclusion: The presence of atopy or allergic diseases does not seem to be related to the severity of COVID-19. However, polysensitization and a family history of allergic diseases are more prominent in those having a cytokine storm and severe COVID-19, respectively. Keywords: COVID-19, atopy, allergic disease, aero-allergen sensitization, cytokine storm
{"title":"Atopy and Allergic Diseases Have No Impact on the Severity of COVID-19","authors":"A. Can, Deniz Eyice Karabacak, C. Tüzer, Alpay Medet ALİBEYOĞLU2, Murat Köse, S. Demir, S. Büyüköztürk, B. Çolakoğlu, A. Gelincik","doi":"10.21911/aai.676","DOIUrl":"https://doi.org/10.21911/aai.676","url":null,"abstract":"Objective: The clinical features of COVID-19 range from asymptomatic disease to severe pneumonia or even death. Therefore, many researchers have investigated the factors that could affect the severity of COVID-19. We aimed to assess the impact of aero-allergen sensitization and allergic diseases on the severity of COVID-19. Materials and Methods: We included 60 adult patients with symptomatic COVID-19 and allocated them into two groups equal in number as having severe and non-severe COVID-19. We evaluated the demographic features and allergic diseases in addition to clinical, laboratory and radiological findings of COVID-19. Skin prick tests (SPTs) with common aero-allergens, serum total IgE levels and blood eosinophil counts were evaluated 3 months after the patient’s recovery from COVID-19.Results: The mean age of the patients was 52 ± 11 years and 73.3% of the patients were male. There was no significant difference between the two groups in terms of age, gender, smoking habits, obesity and comorbidities. Although the frequency of sensitization to aero-allergens and the allergic diseases were similar, the history of allergic diseases in the family was higher in the severe group (p<0.001). The polysensitization in SPTs was associated with the presence of a cytokine storm during the infection (p=0.02). Total IgE levels and blood eosinophil counts were not significantly different between the two groups.Conclusion: The presence of atopy or allergic diseases does not seem to be related to the severity of COVID-19. However, polysensitization and a family history of allergic diseases are more prominent in those having a cytokine storm and severe COVID-19, respectively. Keywords: COVID-19, atopy, allergic disease, aero-allergen sensitization, cytokine storm","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44300923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Buket Daldaban Sarıca, B. Köksal, M. Tekindal, Özlem Yılmaz Özbek
{"title":"Effect of Inhaled Corticosteroid Treatment on Body Composition Parameters in Children with Asthma","authors":"Buket Daldaban Sarıca, B. Köksal, M. Tekindal, Özlem Yılmaz Özbek","doi":"10.21911/aai.634","DOIUrl":"https://doi.org/10.21911/aai.634","url":null,"abstract":"","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42655184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: There is no definitive consensus on asthma exacerbation scoring for preschool children with recurrent wheezing. The Clinical Asthma Score (CAS) and Asthma Severity Score (ASS) are two scoring systems that can be used in this population. The aim of this study was to evaluate the relationship between CAS and ASS, acute treatment, and exacerbation outcomes in preschool children with wheezing. Materials and Methods: The study included 70 patients aged 2-5 years who presented to the pediatric emergency department due to an acute wheezing episode. CAS and ASS were evaluated at exacerbation presentation and after initial salbutamol therapy. Results: Presenting scores were significantly higher among patients who had three or more episodes within the last year (p=0.01 for CAS, p=0.019 for ASS). Presenting scores were significantly higher in patients treated with systemic steroid therapy during the episode compared to those who were not (p=0.006 for CAS; p=0.003 for ASS). CAS and ASS predicted the use of acute steroid therapy with a sensitivity of 73.7% and 52.6%, and predicted hospitalization with a sensitivity of 95% and 82.5%, respectively. Conclusion: Our data suggest that these scoring systems can be used to judge the need for systemic steroid therapy and that high scores are associated with greater likelihood of hospital admission. Keywords: Asthma score, children, hospitalization, wheezing, exacerbation
{"title":"Assessment of Clinical Asthma Score and Asthma Severity Score in Preschool Children with Recurrent Wheezing","authors":"Nurdan Çiftçi, E. Vezir, B. Alioglu","doi":"10.21911/aai.607","DOIUrl":"https://doi.org/10.21911/aai.607","url":null,"abstract":"Objective: There is no definitive consensus on asthma exacerbation scoring for preschool children with recurrent wheezing. The Clinical Asthma Score (CAS) and Asthma Severity Score (ASS) are two scoring systems that can be used in this population. The aim of this study was to evaluate the relationship between CAS and ASS, acute treatment, and exacerbation outcomes in preschool children with wheezing. Materials and Methods: The study included 70 patients aged 2-5 years who presented to the pediatric emergency department due to an acute wheezing episode. CAS and ASS were evaluated at exacerbation presentation and after initial salbutamol therapy. Results: Presenting scores were significantly higher among patients who had three or more episodes within the last year (p=0.01 for CAS, p=0.019 for ASS). Presenting scores were significantly higher in patients treated with systemic steroid therapy during the episode compared to those who were not (p=0.006 for CAS; p=0.003 for ASS). CAS and ASS predicted the use of acute steroid therapy with a sensitivity of 73.7% and 52.6%, and predicted hospitalization with a sensitivity of 95% and 82.5%, respectively. Conclusion: Our data suggest that these scoring systems can be used to judge the need for systemic steroid therapy and that high scores are associated with greater likelihood of hospital admission. Keywords: Asthma score, children, hospitalization, wheezing, exacerbation","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49075628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nazan Tökmeci, A. Demirhan, Merve TURKEGUN SENGUL, Burcu CAGLAR YUKSEK, Aylin KONT ÖZHAN, T. Arıkoğlu, S. Kuyucu
Objective: Allergen-specific immunotherapy (allergen-SIT) is a treatment method with variable efficacy in allergic diseases. This study aimed to investigate the effectiveness of allergen immunotherapy, frequency of LRs and SRs and variables affecting these parameters in patients who underwent allergen-SIT. Materials and Methods: In this study, the recorded data of 81 patients, who received subcutaneous (SCIT) or sublingual (SLIT) allergen immunotherapy for respiratory allergic diseases between 2014 and 2019, were analyzed. In asthma and/or allergic rhinoconjunctivitis (ARC) patients, the effectiveness of treatment was evaluated by analysing the change rates in disease symptom, medication and combined scores (symptom + medication) and visual analog score (VAS). Treatment success was defined by the degree of decrease in scores as; high response above 50%; low response between 20-50%; and failure <20%.Results: The mean age of allergen-SIT initiation was 11.4± 3.1 years. Diagnostic distributions of the patients were asthma (± ARC) in 64.2%, and ARC (without asthma) in 35.8%. The mode of allergen-SIT was SCIT in 77.8% (65% asthma and 35% ARC) and SLIT in 22.2% (61.1% asthma and 38.9% ARC). The main allergens used in allergen-SIT were mite (79%), grass-grain pollen (33.3%), alternaria (9.9%) and olea (8.6%). There was a significant decrease in symptoms, medication, combined and VAS scores in the asthma and ARC groups (p <0.0001), when end-SCIT values were compared to baseline. SLIT also resulted in significant decreases in these scores except asthma medication score. Among the asthma patients the rate of high-responders was 88.8% by SCIT and 50% by SLIT, according to combined asthma score. Among the ARC (without asthma) patients the rate of high-responders was 100% for both SCIT and SLIT. SCIT resulted in local (LR) and systemic side effects (SR) in 18% and 0.6% (all Grade I and Grade II) of the total injections performed. A high number of total injections was significantly associated with higher LR and SR rates. While LR was observed in 16.6% of the patients who underwent SLIT, no systemic reaction was found in any of the patients. Conclusion: SCIT was highly successful in the treatment of asthma and ARC in terms of the degree of therapeutic response. SLIT resulted in a high rate of good response in ARC patients, but a lower response degree in asthmatic patients. Systemic side effects were very low as a result of close risk monitoring and the dose adjustments performed. Keywords: Allergen-specific immunotherapy, SCIT, SLIT, efficacy, symptom score, medication score, visual analog score, side effects
{"title":"Standardized Quantitative Evaluation of Clinical Effectiveness and Side Effect Profile of Subcutaneous and Sublingual Allergen-Specific Immunotherapy in Children: A 5-Year Single Center Experience","authors":"Nazan Tökmeci, A. Demirhan, Merve TURKEGUN SENGUL, Burcu CAGLAR YUKSEK, Aylin KONT ÖZHAN, T. Arıkoğlu, S. Kuyucu","doi":"10.21911/aai.652","DOIUrl":"https://doi.org/10.21911/aai.652","url":null,"abstract":"Objective: Allergen-specific immunotherapy (allergen-SIT) is a treatment method with variable efficacy in allergic diseases. This study aimed to investigate the effectiveness of allergen immunotherapy, frequency of LRs and SRs and variables affecting these parameters in patients who underwent allergen-SIT. Materials and Methods: In this study, the recorded data of 81 patients, who received subcutaneous (SCIT) or sublingual (SLIT) allergen immunotherapy for respiratory allergic diseases between 2014 and 2019, were analyzed. In asthma and/or allergic rhinoconjunctivitis (ARC) patients, the effectiveness of treatment was evaluated by analysing the change rates in disease symptom, medication and combined scores (symptom + medication) and visual analog score (VAS). Treatment success was defined by the degree of decrease in scores as; high response above 50%; low response between 20-50%; and failure <20%.Results: The mean age of allergen-SIT initiation was 11.4± 3.1 years. Diagnostic distributions of the patients were asthma (± ARC) in 64.2%, and ARC (without asthma) in 35.8%. The mode of allergen-SIT was SCIT in 77.8% (65% asthma and 35% ARC) and SLIT in 22.2% (61.1% asthma and 38.9% ARC). The main allergens used in allergen-SIT were mite (79%), grass-grain pollen (33.3%), alternaria (9.9%) and olea (8.6%). There was a significant decrease in symptoms, medication, combined and VAS scores in the asthma and ARC groups (p <0.0001), when end-SCIT values were compared to baseline. SLIT also resulted in significant decreases in these scores except asthma medication score. Among the asthma patients the rate of high-responders was 88.8% by SCIT and 50% by SLIT, according to combined asthma score. Among the ARC (without asthma) patients the rate of high-responders was 100% for both SCIT and SLIT. SCIT resulted in local (LR) and systemic side effects (SR) in 18% and 0.6% (all Grade I and Grade II) of the total injections performed. A high number of total injections was significantly associated with higher LR and SR rates. While LR was observed in 16.6% of the patients who underwent SLIT, no systemic reaction was found in any of the patients. Conclusion: SCIT was highly successful in the treatment of asthma and ARC in terms of the degree of therapeutic response. SLIT resulted in a high rate of good response in ARC patients, but a lower response degree in asthmatic patients. Systemic side effects were very low as a result of close risk monitoring and the dose adjustments performed. Keywords: Allergen-specific immunotherapy, SCIT, SLIT, efficacy, symptom score, medication score, visual analog score, side effects","PeriodicalId":42004,"journal":{"name":"Astim Allerji Immunoloji","volume":" ","pages":""},"PeriodicalIF":0.2,"publicationDate":"2021-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47319489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：